ketamine, FDA and depression

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.
FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.
Ketamine Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
J&J's ketamine-derived nasal spray approved by FDA to treat depression
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray,
J&J’s ketamine-based drug approved as standalone treatment
"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants or cannot tolerate them. For too long, health care providers have had few options to offer patients much-needed symptom improvement,
The FDA just approved this ketamine-derived nasal spray for depression treatment
The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone treatment for adults with major depressive disorder who have not responded to at least two other antidepressants.
Safety and Feasibility of Intranasal Ketamine in Depression Treatment
The following is a summary of “Intranasal racemic ketamine maintenance therapy for patients with treatment-resistant depression: a naturalistic feasibility study,” published in the January 2025 issue of Psychiatry by Halpape et al.
US FDA approves J&J's ketamine-based therapy to treat depression
The U.S. Food and Drug Administration approved Johnson & Johnson's ketamine-based nasal spray Spravato to treat adults with major depressive disorder, the company said on Tuesday. The approval paves the way for use of Spravato in patients whose disease has stopped responding to at least two oral anti-depressants.
Nose spray to treat depression? FDA approves first-of-its-kind medicine
The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.
FDA Clears Spravato For Monotherapy Depression Treatments
The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of depression, officials said. The FDA granted approval to Spravato (esketamine) as the first monotherapy for adults with treatment-resistant depression,
Research indicates recreational ketamine use is on the rise
Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year ...
US Weekly on MSN7d
What Celebrities and Doctors Have Said About Ketamine Use: Chrissy Teigen, Matthew Perry, More
Celebrities like Chrissy Teigen and Matthew Perry have been open about using ketamine for their mental health – here's what ...
Medscape2d
Ketamine-Induced Uropathy: What Urologists Need to Know
A multidisciplinary approach, including ketamine withdrawal and symptom management, is essential to mitigate long-term ...
IFLScience8h
FDA Approves First-Ever Standalone Therapy For Treatment-Resistant Depression
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...
Hosted on MSN7h
Breakthrough study shows how ketamine may ease dyskinesia in Parkinson’s patients
A recent study published in the journal Brain has revealed new insights into the neurological underpinnings of levodopa-induced dyskinesia, a common and debilitating complication of Parkinson’s ...
Ketamine Healing Clinic of Los Angeles and Orange County Honored as 2025 Top Patient Rated Doctor by Find Local Doctors
Dr. David Mahjoubi, a highly respected board-certified anesthesiologist and the founder of Ketamine Healing Clinic of Los Angeles and OC, has been recognized as a 2025 Top Patient Rated Doctor by Find ...